Active	Status	Sponsor type	Region	Phase	Filter
6 Active 16 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
NCT06417489: Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients	Not yet recruiting	4	160	NA	Combination therapy, Sequential treatment group	Peking University First Hospital	Type 2 Diabetes	05/26	12/26
NCT04667143: Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy	Not yet recruiting	3	760	NA	Retagliptin, Henagliflozein, metformin XR	Jiangsu HengRui Medicine Co., Ltd.	Diabetes Mellitus, Type II	09/22	10/22
NCT05054842: Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes	Active, not recruiting	3	174	RoW	Retagliptin phosphate tablets、metformin sustained-release tablets, Retagliptin phosphate placebo tablets、metformin sustained-release tablets	Jiangsu HengRui Medicine Co., Ltd.	Type 2 Diabetes	12/23	12/23
ChiCTR-OPC-15006905: Mass Balance of Retagliptin to healthy subjects in a single-dose Phase I study	Recruiting	1	8		100mg Retagliptin single dose	Beijing Shijitan Hospital Capital Medical University; Jiangsu Hengrui Medicine Co. LTD, Jiangsu Hengrui Medicine Co. LTD	Diabetes
NCT06035406: A Trial of SP2086 With Hepatic Insufficiency	Not yet recruiting	1	24	NA	Retagliptin Phosphate Tablet	Jiangsu HengRui Medicine Co., Ltd.	Diabetes	12/23	12/23
ChiCTR2500099813: Safety and efficacy of Retagliptin in Chinese patients with type 2 diabetes.	Recruiting	N/A	2500		Retagliptin	The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university, Jiangsu Hengrui Pharmaceutical Co., LTD	Type 2 diabetes.

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
NCT06417489: Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients	Not yet recruiting	4	160	NA	Combination therapy, Sequential treatment group	Peking University First Hospital	Type 2 Diabetes	05/26	12/26
NCT04667143: Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy	Not yet recruiting	3	760	NA	Retagliptin, Henagliflozein, metformin XR	Jiangsu HengRui Medicine Co., Ltd.	Diabetes Mellitus, Type II	09/22	10/22
NCT05054842: Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes	Active, not recruiting	3	174	RoW	Retagliptin phosphate tablets、metformin sustained-release tablets, Retagliptin phosphate placebo tablets、metformin sustained-release tablets	Jiangsu HengRui Medicine Co., Ltd.	Type 2 Diabetes	12/23	12/23
ChiCTR-OPC-15006905: Mass Balance of Retagliptin to healthy subjects in a single-dose Phase I study	Recruiting	1	8		100mg Retagliptin single dose	Beijing Shijitan Hospital Capital Medical University; Jiangsu Hengrui Medicine Co. LTD, Jiangsu Hengrui Medicine Co. LTD	Diabetes
NCT06035406: A Trial of SP2086 With Hepatic Insufficiency	Not yet recruiting	1	24	NA	Retagliptin Phosphate Tablet	Jiangsu HengRui Medicine Co., Ltd.	Diabetes	12/23	12/23
ChiCTR2500099813: Safety and efficacy of Retagliptin in Chinese patients with type 2 diabetes.	Recruiting	N/A	2500		Retagliptin	The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university, Jiangsu Hengrui Pharmaceutical Co., LTD	Type 2 diabetes.